NEW YORK (GenomeWeb News) – HX Diagnostics said today that it has expanded a license and development agreement with Nanogen, under which the companies will develop rapid, point-of-care diagnostics for respiratory infectious diseases.
The agreement builds on a development program from 2006 that has been using Nanogen’s fluID Rapid Influenza Test, which was developed with a $4.5 million grant from the U.S. Centers for Disease Control and Prevention. The firms are developing a fluid test that detects multiple strains and subtypes of influenza, including avian influenza, in one test.
The new agreement will focus on the same underlying lateral flow technology and device design as in the fluID test, the Emeryville, Calif.-based company said.
HX Diagnostics is owned by venture capital firm Kleiner Perkins Caufield & Byers, and was founded in 2006 to develop diagnostics under the parent company’s Pandemic Preparedness and Biodefense Initiative.
When the joint development program is finished, HX Diagnostics will have an exclusive commercial license to make and sell any resulting products that receive regulatory approval.
HX Diagnostics also said it is developing a testing platform that can be tailored for rapid updates as new strains of seasonal or potentially pandemic disease arise.